AU2019338955B2 - Bispecific antibody targeting IL-1R1 and NLRP3 - Google Patents

Bispecific antibody targeting IL-1R1 and NLRP3

Info

Publication number
AU2019338955B2
AU2019338955B2 AU2019338955A AU2019338955A AU2019338955B2 AU 2019338955 B2 AU2019338955 B2 AU 2019338955B2 AU 2019338955 A AU2019338955 A AU 2019338955A AU 2019338955 A AU2019338955 A AU 2019338955A AU 2019338955 B2 AU2019338955 B2 AU 2019338955B2
Authority
AU
Australia
Prior art keywords
antibody
seq
nlrp3
modulator
nlrp3 inflammasome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019338955A
Other languages
English (en)
Other versions
AU2019338955A1 (en
Inventor
Victoria MCGILLIGAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ulster University
Original Assignee
Ulster University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulster University filed Critical Ulster University
Publication of AU2019338955A1 publication Critical patent/AU2019338955A1/en
Application granted granted Critical
Publication of AU2019338955B2 publication Critical patent/AU2019338955B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019338955A 2018-09-14 2019-09-16 Bispecific antibody targeting IL-1R1 and NLRP3 Active AU2019338955B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1815045.8 2018-09-14
GBGB1815045.8A GB201815045D0 (en) 2018-09-14 2018-09-14 Bispecific antibody targeting IL-1R1 and NLPR3
PCT/EP2019/074745 WO2020053447A1 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting il-1r1 and nlpr3

Publications (2)

Publication Number Publication Date
AU2019338955A1 AU2019338955A1 (en) 2021-04-15
AU2019338955B2 true AU2019338955B2 (en) 2026-03-19

Family

ID=64013420

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019338955A Active AU2019338955B2 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting IL-1R1 and NLRP3
AU2019338674A Active AU2019338674B2 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting IL-1R1 and NLRP3

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019338674A Active AU2019338674B2 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting IL-1R1 and NLRP3

Country Status (7)

Country Link
US (2) US12264201B2 (enExample)
EP (2) EP3849662A1 (enExample)
JP (3) JP7517702B2 (enExample)
CN (2) CN112996564A (enExample)
AU (2) AU2019338955B2 (enExample)
GB (1) GB201815045D0 (enExample)
WO (2) WO2020053446A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
JP2024501033A (ja) * 2020-12-28 2024-01-10 エムディー ヘルスケア インコーポレイテッド ミクロコッカス・ルテウス由来細胞外小胞を含む眼疾患の予防または治療用組成物
US20250382341A1 (en) * 2022-12-30 2025-12-18 The Regents Of The University Of California Methods and compositions of in vivo engineering of t-cells to anti-inflammatory cells and therapeutic applications there of
CN119925593B (zh) * 2023-06-05 2025-11-25 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂
CN120535628B (zh) * 2023-06-05 2025-11-25 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502064A (ja) * 2014-01-10 2017-01-19 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1266004A2 (en) 2000-02-17 2002-12-18 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2001296333A1 (en) 2000-09-26 2002-04-08 The Burnham Institute Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
US20080008652A1 (en) 2006-01-10 2008-01-10 The Regents Of The University Of Michigan Methods and compositions for mediation of immune responses and adjuvant activity
FR2937339B1 (fr) 2008-10-21 2013-02-15 Univ Bourgogne Procede de detection de la maladie atheromateuse.
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2011109459A2 (en) 2010-03-04 2011-09-09 University Of Miami Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases
CA2808185A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1.beta. and il-18, for treatment of disease
US9707272B2 (en) * 2011-07-12 2017-07-18 Universitat Zurich Method for the treatment of acne by administering IL-1β antibody
US10633451B2 (en) * 2012-02-03 2020-04-28 Hoffmann-La Roche Inc. Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
EP2812697B1 (en) 2012-02-06 2017-03-22 University of Miami Innate immune proteins as biomarkers for cns injury
EP2825561A4 (en) 2012-03-15 2016-03-09 Permeon Biolog Inc CELL PENETRATING COMPOSITIONS FOR THE DISPOSAL OF INTRA-CELLULAR ANTIBODIES AND ANTIBODY-RELATED UNITS AND METHODS OF USE
US20160354437A1 (en) * 2014-02-13 2016-12-08 Northwestern University Compositions and methods for modulation of immune response
CN104258398B (zh) * 2014-10-14 2017-12-22 中国科学技术大学 Drd1及其激动剂在制备治疗nlrp3炎症小体相关炎症性疾病药物中的用途
US20170145412A1 (en) 2015-11-04 2017-05-25 Idera Pharmaceuticals, Inc. Compositions for inhibiting nlrp3 gene expression and uses thereof
JP2019069905A (ja) * 2016-02-29 2019-05-09 国立大学法人大阪大学 組織損傷治療剤
US20200115358A1 (en) * 2016-03-11 2020-04-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin and icaritin derivatives
WO2018022982A1 (en) * 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502064A (ja) * 2014-01-10 2017-01-19 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用

Also Published As

Publication number Publication date
JP2024125385A (ja) 2024-09-18
EP3849661A1 (en) 2021-07-21
AU2019338674A1 (en) 2021-04-22
US12227579B2 (en) 2025-02-18
AU2019338955A1 (en) 2021-04-15
JP2022500457A (ja) 2022-01-04
US20220041739A1 (en) 2022-02-10
US20220033507A1 (en) 2022-02-03
GB201815045D0 (en) 2018-10-31
JP2022500455A (ja) 2022-01-04
CN112996564A (zh) 2021-06-18
WO2020053446A1 (en) 2020-03-19
JP7517702B2 (ja) 2024-07-17
CN112996563A (zh) 2021-06-18
AU2019338674B2 (en) 2026-02-05
EP3849662A1 (en) 2021-07-21
JP7645544B2 (ja) 2025-03-14
WO2020053447A1 (en) 2020-03-19
US12264201B2 (en) 2025-04-01

Similar Documents

Publication Publication Date Title
AU2019338955B2 (en) Bispecific antibody targeting IL-1R1 and NLRP3
JP2023159314A (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
JP2022020636A (ja) Ｐｓｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト
CN105111310B (zh) 抗nogo-66受体(ngr)的中和单克隆抗体及其用途
JP7352973B2 (ja) 二重特異性抗体及びその使用
BR112020009707A2 (pt) anticorpos para a-sinucleína e usos dos mesmos
TWI547501B (zh) 用於中和血管內皮生長因子之重組單株抗體vNAR
AU2021416127A1 (en) Pd-1 binding molecule and application thereof
US20250333536A1 (en) Mageb2 binding constructs
CA2843921A1 (en) Antibodies against phosphorylcholine
CA2843960A1 (en) Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
US20220372159A1 (en) Treatment and Prevention of Ischemic Diseases And/Or Ischemic Tissue Damages
TWI603979B (zh) 抗人類膜錨定型免疫球蛋白a抗體能夠溶解帶有膜錨定型免疫球蛋白a的b淋巴球與降低免疫球蛋白a 的生產
US10081678B2 (en) Specific binding antibodies of glycoprotein IB alpha as selective ectodomain shedding inhibitors
WO2022136457A1 (en) Nanobody to glycoprotein vi
BR122025018375A2 (pt) Fragmentos de cadeia única de anticorpo anti-c3
HK1195249A (en) Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof